Werewolf Therapeutics appoints Dr. Michael B. Atkins, cancer immunotherapy expert, to board

Werewolf Therapeutics, Inc.

Dr. Atkins appointed as Class III director effective Jan. 4, 2024; will serve until 2024 annual meeting.
He brings over 30 years of translational and clinical research in melanoma, kidney cancer, and immunotherapy.
Appointed to Nominating and Corporate Governance Committee.
Receives annual cash compensation of $40,000 plus $4,000 committee fee; granted option for 35,000 shares at $5.25.
Option vests one-third on first anniversary, then monthly over three years, subject to continued service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael B. Atkins

director

HOWL · Werewolf Therapeutics, Inc.

Effective: 2024-01-04
Filed: January 4, 2024, 6:59 PM ET

On January 4, 2024, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Michael B. Atkins, M.D., as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael B. Atkins was appointed as director at Werewolf Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On January 4, 2024, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Michael B. Atkins, M.D., as a director.

View on SEC.gov

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-002523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.